Metraipolis › archive › dc_675f4e9108ce

Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide — Europe PMC PMID:41378317

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41378317
DOI
10.1016/j.ajpc.2025.101352
License (as archived)
solo-consultazione
Archived
2026-11-08T13:01:24.329Z
SHA-256 of the archived text
8dafc096d2cd856fbde1556ae19a61e3dfaf01f42e72d3114694cfb1335118c6
Stable URL of this page
https://metraipolis.com/documento/dc_675f4e9108ce

How to cite

Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide — Europe PMC PMID:41378317 — Europe PMC (en), https://europepmc.org/article/MED/41378317 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_675f4e9108ce (Metraipolis archive dc_675f4e9108ce, sha256 8dafc096d2cd856fbde1556ae19a61e3dfaf01f42e72d3114694cfb1335118c6)
BibTeX
@misc{dc675f4e9108ce,
  title = {Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide — Europe PMC PMID:41378317},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41378317},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_675f4e9108ce; sha256 8dafc096d2cd856fbde1556ae19a61e3dfaf01f42e72d3114694cfb1335118c6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41378317. Agents can read the archived copy with the MCP tool read_document.